R Squared Ltd Purchases Shares of 9,010 Sanofi $SNY

R Squared Ltd purchased a new stake in Sanofi (NASDAQ:SNY) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 9,010 shares of the company’s stock, valued at approximately $435,000.

Other hedge funds have also recently bought and sold shares of the company. Accent Capital Management LLC bought a new position in Sanofi in the first quarter valued at approximately $29,000. Eastern Bank grew its stake in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Sanofi in the second quarter valued at approximately $28,000. Golden State Wealth Management LLC grew its stake in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Finally, Banque Transatlantique SA bought a new position in Sanofi in the first quarter valued at approximately $33,000. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. Finally, Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $62.67.

Sanofi Stock Performance

SNY opened at $51.64 on Friday. The business has a fifty day simple moving average of $48.65 and a 200 day simple moving average of $49.55. The company has a market capitalization of $126.80 billion, a PE ratio of 12.41, a price-to-earnings-growth ratio of 1.20 and a beta of 0.51. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.73 earnings per share. Research analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.